Fully automated synthesis procedure of 4-[18F]fluorobenzaldehyde by commercial synthesizer: Amino-oxi peptide labelling prosthetic group

Applied Radiation and Isotopes

Volumn 67, Issue 9, 2009, Pages 1664-1669

  Speranza, Antonio ^a   Ortosecco, Giovanni ^a   Castaldi, Elena ^a   Nardelli, Anna ^b   Pace, Leonardo ^b   Salvatore, Marco ^b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

18F; Automated synthesis system; Peptides; PET; Radiohalogenation

Indexed keywords

18F; ACTIVITY RECOVERY; AUTOMATED SYNTHESIS; AUTOMATED SYNTHESIS SYSTEM; AUTOMATIC SYNTHESIS; CLINICAL ROUTINE; FUNCTIONALIZED; ONE-POT SYNTHESIS; PET; PROSTHETIC GROUPS; RADIOCHEMICAL PURITY; RADIOCHEMICAL YIELD; RADIOHALOGENATION; SOLID-PHASE EXTRACTION;

AMINATION; AUTOMATION; EXTRACTION; PEPTIDES; PROJECTILES; PROSTHETICS; PURIFICATION;

AMINES;

4 FLUOROBENZALDEHYDE F 18; PEPTIDE; PHENYL GROUP; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; CHEMICAL LABELING; DRUG PURITY; DRUG SYNTHESIS; PRIORITY JOURNAL; PURIFICATION; RADIOACTIVITY; REACTOR; SOLID PHASE EXTRACTION;

BENZALDEHYDES; FLUORINE RADIOISOTOPES; ISOTOPE LABELING; PEPTIDES; RADIOPHARMACEUTICALS;

EID: 67349087391     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2009.04.008     Document Type: Article

References (17)

1. Bergmann R., Scheunemann M., Heichert C., et al. Biodistribution and catabolism of 18F-labelled neurotensin (8-13) analogs. Nucl. Med. Biol. 29 (2002) 61-72
2. 18F]fluorobenzylidene)aminooxyhexyl]maleimide. Nucl. Med. Biol. 34 (2007) 5-15
3. 18F-fluorinated aldehydes. Nucl. Med. Biol. 33 (2006) 173-183
4. Fredriksson A., Ekberg K., Ingvar M., Johansson B.L., Wahren J., and Stone-Elander S. In vivo biodistribution and pharmacokinetics of 18F-labeled human C-peptide: evaluation in monkeys using positron emission tomography. Life Sci. 71 (2002) 1361-1370
5. Haubner R., Wester H.J., Weber W.A., et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61 (2001) 1781-1785
6. Iwata R., Pascali C., Bogni A., et al. A new convenient method for the preparation of 4-[18F]fluorobenzylhalides. Appl. Radiat. Isot. 52 (2000) 87-92
7. 3 receptor partial agonist. Bioorg. Med. Chem. 6 (1998) 789-795
8. 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK). Nucl. Med. Biol. 33 (2006) 677-683
9. Lemaire C., Damhaut P., Plenevaux A., and Comar D. Enantioselective synthesis of 6-[fluorine-18]-fluoro-l-dopa from no-carrier-added fluorine-18-fluoride. J. Nucl. Med. 35 (1997) 1996-2002
10. 18F]SFB). Appl. Radiat. Isot. 63 (2005) 329-332
11. 18F]fluorobenzoate using a Siemens/CTI chemistry process control unit (CPCU). Appl. Radiat. Isot. 65 (2007) 199-203
12. Okarvi S.M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur. J. Nucl. Med. 28 (2001) 929-938
13. Poethko T., Schottelius M., Thumshirn G., et al. Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J. Nucl. Med. 45 (2004) 892-902
14. 18F]F-A-85380). Appl. Radiat. Isot. 65 (2007) 1244-1248
15. Stöcklin G.L. Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)?. Eur. J. Nucl. Med. 25 (1998) 1612-1616
16. Stöcklin, G., Wester, H.J., 1998. Strategies for radioligand development: peptides for tumor targeting. In: Gulyas, B., Müller-Gärtner, H.W. (Eds.), Positron Emission Tomography: A Critical Assessment of Recent Trends. Kluwer Academic, Dordrecht, The Netherlands, pp. 57-90.
17. Toyokuni T., Walsh J.S., Dominguez A., Phelps M.E., Barrio J.R., Gambhir S.S., and Satyamurthy N. Synthesis of a new heterobifunctional linker, N-[4-(aminooxy)butyl]maleimide, for facile access to a thiol-reactive 18F-labeling agent. Bioconjugate Chem. 14 6 (2003) 1253-1259